PRIMATENE MIST Drug Patent Profile

Which patents cover Primatene Mist, and what generic alternatives are available?

Primatene Mist is a drug marketed by Armstrong Pharms and Wyeth Cons and is included in two NDAs. There is one patent protecting this drug.

The generic ingredient in PRIMATENE MIST is epinephrine. There are twenty-one drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the epinephrine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Primatene Mist

A generic version of PRIMATENE MIST was approved as epinephrine by BPI LABS on July 29^th, 2014.

Summary for PRIMATENE MIST

US Patents:	1
Applicants:	2
NDAs:	2

US Patents and Regulatory Information for PRIMATENE MIST

PRIMATENE MIST is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Armstrong Pharms	PRIMATENE MIST	epinephrine	AEROSOL, METERED;INHALATION	205920-001	Nov 7, 2018		OTC	Yes	Yes			Y
Wyeth Cons	PRIMATENE MIST	epinephrine	AEROSOL, METERED;INHALATION	016126-001	Approved Prior to Jan 1, 1982		DISCN	No	No

PRIMATENE MIST: INVESTMENT AND FUNDAMENTALS ANALYSIS

Last updated: February 19, 2026

This report provides an investment scenario and fundamentals analysis for Primatene Mist, a non-prescription asthma inhaler containing epinephrine. The drug's market position is shaped by regulatory history, competitive landscape, and potential for future market access.

What is Primatene Mist?

Primatene Mist is an over-the-counter (OTC) inhaler that delivers epinephrine, a bronchodilator. It is indicated for the temporary relief of mild symptoms of intermittent asthma. The active ingredient, epinephrine, works by relaxing the muscles in the airways, allowing for easier breathing.

The product was historically available OTC but was withdrawn from the market in 2011 due to concerns raised by the U.S. Food and Drug Administration (FDA) regarding its safety and efficacy for unsupervised use by individuals with asthma, particularly those with severe or persistent asthma. The FDA reclassified epinephrine as a Category I drug for OTC use, meaning it required a prescription. This action effectively removed Primatene Mist from consumer availability [1].

In 2018, after a protracted regulatory process, the FDA permitted the reintroduction of Primatene Mist to the OTC market under specific conditions. This reapproval was contingent on the drug being solely indicated for the temporary relief of mild symptoms of intermittent asthma, and it explicitly excluded individuals with moderate to severe or persistent asthma [2]. The labeling was updated to emphasize these limitations and to advise users to seek medical attention if symptoms persist or worsen.

Market Landscape and Competitive Factors

The competitive landscape for asthma treatment is broadly divided into prescription medications and, historically and now with Primatene Mist's return, OTC options.

Prescription Asthma Medications

Prescription asthma treatments encompass a wide range of drug classes, including:

• Inhaled Corticosteroids (ICS): These are the cornerstone of long-term asthma control. Examples include fluticasone propionate (Flovent), budesonide (Pulmicort), and mometasone furoate (Asmanex) [3]. They reduce inflammation in the airways.
• Long-Acting Beta-Agonists (LABAs): Often used in combination with ICS, LABAs provide long-acting bronchodilation. Examples include salmeterol (Serevent) and formoterol (Foradil) [3]. They are not to be used as monotherapy for asthma.
• Short-Acting Beta-Agonists (SABAs): These provide rapid, short-term relief of bronchospasm. Albuterol (ProAir, Ventolin, Proventil) is the most common SABA and is available by prescription and in some OTC formulations with specific labeling.
• Leukotriene Modifiers: Drugs like montelukast (Singulair) block the action of leukotriene, which contributes to airway inflammation and bronchoconstriction [3].
• Biologics: For severe, uncontrolled asthma, advanced therapies targeting specific inflammatory pathways are available, such as omalizumab (Xolair) and dupilumab (Dupixent) [3].

The prescription market is characterized by significant innovation, extensive clinical trials, and a robust intellectual property landscape. Pharmaceutical companies invest heavily in developing newer, more targeted, and more effective therapies for various asthma severities.

Over-the-Counter (OTC) Asthma Options

Prior to its withdrawal, Primatene Mist was a dominant player in the OTC asthma relief segment. Its reintroduction places it in a niche market with limited direct competition for its specific formulation and indication.

Currently, the primary OTC competitor to Primatene Mist is AsthmaCare (epinephrine bitartrate). This product offers a similar indication for temporary relief of mild asthma symptoms. However, Primatene Mist has a longer brand history and, with its reintroduction, aims to recapture market share.

The key differentiator for Primatene Mist is its specific indication: mild, intermittent asthma. This is a critical limitation. It means the product is not intended for or safe for individuals with more severe asthma presentations, where prescription therapies are essential.

Table 1: Comparison of OTC Asthma Relief Products

Feature	Primatene Mist	AsthmaCare
Active Ingredient	Epinephrine	Epinephrine bitartrate
Indication	Temporary relief of mild symptoms of intermittent asthma	Temporary relief of mild asthma symptoms
Availability	Over-the-counter (OTC)	Over-the-counter (OTC)
Target User	Individuals with mild, intermittent asthma	Individuals with mild asthma symptoms
Regulatory Status	FDA-approved for OTC sale (post-2018)	FDA-approved for OTC sale
Brand Recognition	High (historical)	Moderate
Prescription Req.	No	No

The OTC market for asthma relief is significantly smaller than the prescription market. Its growth is constrained by the stringent labeling requirements and the FDA's clear delineation of appropriate use cases.

Regulatory and Legal Considerations

The regulatory journey of Primatene Mist is central to its current market position and future outlook. The FDA's stance on OTC epinephrine for asthma has been shaped by evolving scientific understanding and a focus on patient safety.

FDA Reclassification and Reintroduction

The FDA's decision to reclassify epinephrine as a Category I drug for OTC use in 2011 led to the withdrawal of Primatene Mist. This decision was based on studies and public health concerns indicating that unsupervised use of epinephrine by individuals with moderate to severe asthma could lead to delayed diagnosis, inadequate treatment, and potentially serious adverse events [1]. The FDA concluded that epinephrine was not safe and effective for unsupervised use for the broad spectrum of asthma patients.

The subsequent reapproval in 2018 was a result of significant efforts by the manufacturer to meet FDA requirements for updated labeling and marketing restrictions. The revised approval stipulated that Primatene Mist could only be marketed for the temporary relief of mild symptoms of intermittent asthma. This means the product is intended for occasional, mild breathing difficulties, not for daily or severe symptoms that require ongoing management [2].

Key stipulations for reintroduction included:

• Clear and prominent labeling warnings against use by individuals with moderate to severe or persistent asthma.
• Advisories to seek immediate medical attention if symptoms do not improve or worsen.
• Restrictions on marketing and promotion to ensure the product is not perceived as a substitute for prescription long-term control medications.

Potential Legal Challenges and Safety Post-Market Surveillance

While the product is back on the market, the FDA will maintain a close watch on its post-market performance. Any evidence of misuse, adverse event trends suggestive of off-label use, or failure to adhere to labeling requirements could trigger further regulatory action, including potential withdrawal.

Legal challenges could arise if there are a significant number of adverse events linked to the product's use, especially if it can be demonstrated that the labeling was insufficient or that marketing contributed to misuse. Competitors or consumer advocacy groups could also challenge the regulatory approval if they believe it poses an undue risk.

Financial and Investment Outlook

Analyzing Primatene Mist from an investment perspective requires considering its niche market, regulatory constraints, and brand potential.

Revenue Streams and Profitability

Primatene Mist's revenue is generated through direct sales to consumers via pharmacies and other retail outlets. As an OTC product, it does not involve complex reimbursement negotiations with private payers or government programs, which simplifies the revenue cycle. However, OTC drug margins are generally lower than those for patented prescription drugs.

Profitability will depend on:

• Sales Volume: The number of units sold will be directly tied to consumer adoption and adherence to the product's indicated use.
• Manufacturing Costs: Production efficiency and supply chain management are critical for maintaining healthy profit margins.
• Marketing and Distribution Expenses: While not a prescription drug, effective marketing and broad distribution are necessary to reach the target consumer.
• Pricing Strategy: The price point must be competitive within the OTC segment while reflecting the product's value.

Given its reintroduction, initial sales may be driven by brand recognition and pent-up demand from its previous availability. However, long-term growth will depend on establishing a consistent consumer base within the strictly defined "mild, intermittent asthma" segment.

Market Size and Growth Potential

The addressable market for Primatene Mist is significantly smaller than the overall asthma market. It is limited to individuals who self-diagnose or are diagnosed with mild, intermittent asthma and who opt for an OTC solution.

Estimating the precise size of this niche is challenging. However, general asthma prevalence data from the CDC indicates that approximately 25 million Americans have asthma. Of these, a subset experiences mild, intermittent symptoms, and an even smaller proportion chooses OTC treatment over seeking prescription care or utilizing other OTC symptomatic relief.

Growth potential is constrained by:

• Strict FDA Indications: The inability to market or be used for moderate to severe asthma limits the user base.
• Competition from Prescription Medications: For many individuals with asthma, prescription-strength inhalers, even SABAs like albuterol, are the standard of care and are often preferred for their efficacy and safety profiles, even for intermittent symptoms.
• Consumer Education: Ensuring consumers understand the specific indications and limitations is crucial. Misinformation or misunderstanding could lead to improper use and negative outcomes.

The potential for Primatene Mist to gain significant market share relies on effectively communicating its precise utility to a specific demographic and its ability to maintain consumer trust in its safety and efficacy within that narrow scope.

Investment Thesis Considerations

An investment in Primatene Mist, or a company associated with its manufacturing and distribution, would be based on several factors:

1. Niche Market Capture: Success hinges on dominating the limited OTC market for mild, intermittent asthma relief.
2. Brand Loyalty and Recognition: Leveraging the historical brand awareness to attract consumers.
3. Regulatory Stability: The absence of significant post-market regulatory issues is paramount.
4. Cost Management: Efficient operations to ensure profitability on lower-margin OTC sales.

Conversely, investment risks include:

1. Limited Growth Ceiling: The inherent constraints on market size due to regulatory indications.
2. Adverse Event Risk: Potential for safety concerns to emerge, leading to regulatory intervention.
3. Competition: While direct OTC competition is limited, the availability of prescription SABAs presents an indirect competitive threat.
4. Shifting Treatment Paradigms: Evolving asthma management guidelines could further emphasize prescription therapies.

The financial outlook is one of stable, albeit modest, revenue generation from a well-defined market segment, contingent on ongoing regulatory compliance and effective market penetration within its defined niche. Significant upside potential is unlikely without a shift in its regulatory status or an expansion of its indicated uses, which are improbable given its history.

Key Takeaways

Primatene Mist operates in a narrowly defined OTC market segment for mild, intermittent asthma symptoms. Its reintroduction after a period of withdrawal underscores the FDA's stringent safety and efficacy requirements for OTC drug products, particularly those with a history of regulatory concern. The product's success is predicated on strict adherence to its limited indications, effective consumer education regarding its appropriate use, and continued regulatory compliance. The competitive landscape includes prescription medications that serve a broader range of asthma severity, and indirect competition from other OTC symptomatic relief options. Investment in Primatene Mist is characterized by potential for stable, niche revenue generation, but is limited by significant regulatory constraints and a constrained growth ceiling.

Frequently Asked Questions

1. What specific asthma symptoms does Primatene Mist treat? Primatene Mist is indicated for the temporary relief of mild symptoms of intermittent asthma, such as occasional wheezing, shortness of breath, or chest tightness, that are not associated with persistent or severe asthma.

2. Can Primatene Mist be used by individuals with moderate to severe asthma? No. Primatene Mist is explicitly contraindicated and unsafe for individuals with moderate to severe or persistent asthma. Its labeling strictly warns against its use in these patient populations.

3. What are the primary risks associated with using Primatene Mist? The primary risks involve delayed diagnosis and inadequate treatment if used by individuals with more severe asthma, potentially leading to serious adverse events. Misuse due to misunderstanding of indications can also lead to adverse health outcomes.

4. What is the difference between Primatene Mist and prescription albuterol inhalers? Primatene Mist contains epinephrine and is approved for OTC use for mild, intermittent asthma. Prescription albuterol inhalers contain albuterol sulfate, a more potent and longer-acting bronchodilator, and are available by prescription for a wider range of asthma severity and control, including for more frequent or severe symptoms.

5. What led to Primatene Mist's previous withdrawal from the market? Primatene Mist was withdrawn in 2011 because the FDA determined that epinephrine was not safe and effective for unsupervised use by the broad spectrum of asthma patients, citing concerns about delayed diagnosis of more serious asthma and potential for adverse events in those with moderate to severe disease.

Citations

[1] Food and Drug Administration. (2011, July 22). FDA proposes to reclassify epinephrine bronchodilator products from over-the-counter (OTC) to prescription drugs. U.S. Department of Health and Human Services. https://www.fda.gov/news-events/press-announcements/fda-proposes-reclassify-epinephrine-bronchodilator-products-over-counter-otc-prescription-drugs

[2] Food and Drug Administration. (2018, October 23). FDA permits marketing of Primatene Mist for mild, intermittent asthma. U.S. Department of Health and Human Services. https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-primatene-mist-mild-intermittent-asthma

[3] Global Initiative for Asthma. (2023). GINA Report, Global Strategy for Asthma Management and Prevention. https://ginasthma.org/reports/